HeartSciences Inc. (NASDAQ:HSCS – Get Free Report) was the recipient of a significant growth in short interest in the month of October. As of October 15th, there was short interest totaling 63,146 shares, a growth of 126.1% from the September 30th total of 27,931 shares. Based on an average daily volume of 332,122 shares, the days-to-cover ratio is currently 0.2 days. Approximately 1.3% of the company’s shares are sold short.
HeartSciences Stock Performance
Shares of HeartSciences stock traded down $0.30 during trading hours on Friday, hitting $3.31. The company’s stock had a trading volume of 54,480 shares, compared to its average volume of 742,291. HeartSciences has a twelve month low of $1.63 and a twelve month high of $5.25. The firm has a fifty day moving average of $3.59 and a 200-day moving average of $2.73. The stock has a market cap of $16.45 million, a price-to-earnings ratio of -1.03 and a beta of 1.76.
HeartSciences (NASDAQ:HSCS – Get Free Report) last issued its quarterly earnings data on Monday, September 14th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.14). The company had revenue of $0.00 million during the quarter, compared to analysts’ expectations of $0.10 million. On average, sell-side analysts expect that HeartSciences will post -2.99 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of brokerages have commented on HSCS. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of HeartSciences in a research note on Monday, September 21st. Wall Street Zen raised shares of HeartSciences from a “sell” rating to a “hold” rating in a research note on Sunday, September 20th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $8.00.
Check Out Our Latest Analysis on HSCS
About HeartSciences
HeartSciences, Inc (NASDAQ: HSCS) is a medical technology company focused on improving the detection and assessment of heart disease through advanced electrocardiography (ECG). The company develops diagnostic tools designed to provide clinicians with additional information about cardiac function using a standard, noninvasive ECG test.
Its principal technology is the MyoVista ECG system, which uses the company’s proprietary wavelet-based ECG, or wavECG, technology. MyoVista is designed to assess mechanical aspects of the heart, including left ventricular diastolic function, which may help identify cardiac abnormalities that are not readily detected through conventional ECG analysis.
Further Reading
- Five stocks we like better than HeartSciences
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
Receive News & Ratings for HeartSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HeartSciences and related companies with MarketBeat.com's FREE daily email newsletter.
